Skip to main content
. 2021 Jul 27;4(7):e2114501. doi: 10.1001/jamanetworkopen.2021.14501

Figure 2. Sensitivity Analyses.

Figure 2.

In panel A, the blue dashed line indicates the assumed cost-effectiveness threshold of $100 000 per quality-adjusted life years (QALYs) gained (blue dashed line). Adding dapagliflozin to GDMT was cost-effective in 94% of 10 000 probabilistic simulations.